BioCentury
ARTICLE | Company News

Baxter renal, neurology news

October 15, 2012 7:00 AM UTC

At its 2012 investor conference, Baxter announced two new companies in its venture fund's investment portfolio. The fund plans to invest $2.5 million in a Vienna-based company Baxter refers to as Baxter Ventures 801, which is developing a cytoprotective peptide to improve peritoneal immune competence and protect peritoneal membrane integrity. The newco plans to start a Phase IIa trial early next year for end-stage renal disease (ESRD).

The fund also plans to co-lead a series C round with $10 million for a company Baxter refers to as Baxter Ventures 102, which is developing an IV formulation of a partial NMDA receptor agonist for acute depression. The company plans to start a Phase IIb trial this quarter. Baxter declined to disclose additional details on the investments. ...